A major impediment in the development of peptide-based therapeutics is our inability to successfully deliver and maintain them at their intended site of action. The present review will focus on a novel, unique, chemicalenzymatic approach designated as molecular packaging that represents an extension of the redox chemical delivery system (CDS) approach and can provide brain- and retina- targeted delivery of peptides through rational drug design. This has made possible the non-invasive brain delivery of neuropeptides such as Leuenkephalin-, TRH-, and kyotorphin-analogs in pharmacologically significant and therapeutically effective amounts.
|Original language||English (US)|
|Number of pages||5|
|Journal||American Pharmaceutical Review|
|State||Published - Jan 1 2006|
ASJC Scopus subject areas
- Pharmaceutical Science